Palvella Therapeutics PVLA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's accounts payable?
- Palvella Therapeutics (PVLA) reported accounts payable of $5.44M in Q1 2026.
- How has Palvella Therapeutics's accounts payable changed year-over-year?
- Palvella Therapeutics's accounts payable increased by 22.6% year-over-year, from $4.44M to $5.44M.
- What is the long-term trend for Palvella Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Palvella Therapeutics's accounts payable has grown at a 20.8% compound annual growth rate (CAGR), from $1.79M to $4.6M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.